2seventy Bio, Inc. TSVT
Institutional shares held
45.6 Million
122K
calls
19.8K
puts
Total value of holdings
$179M
$478K
calls
$77K
puts
Market Cap
$149M
37,873,600
Shares Out.
Institutional ownership
120.3%
# of Institutions
126
We take great care to ensure that the data presented and summarized in this overview for 2seventy bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TSVT
View all-
Kynam Capital Management, LP Princeton, NJ5.95MShares$23.4 Million2.31% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$16.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$14.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$14.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.89MShares$11.4 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY2.56MShares$10.1 Million1.49% of portfolio
-
Newtyn Management, LLC New York, NY2.54MShares$9.98 Million2.12% of portfolio
-
Baker Bros. Advisors LP New York, NY2.5MShares$9.82 Million0.13% of portfolio
-
Casdin Capital, LLC New York, NY2MShares$7.86 Million0.73% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.33MShares$5.23 Million0.0% of portfolio
Latest Institutional Activity in TSVT
Top Purchases
Top Sells
About TSVT
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at TSVT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Jessica Snow |
SELL
Open market or private sale
|
Direct |
2,287
-1.47%
|
$6,861
$3.23 P/Share
|
|
Nov 18
2024
|
Marcela V. Maus |
SELL
Open market or private sale
|
Direct |
3,900
-14.1%
|
$11,700
$3.38 P/Share
|
|
Oct 03
2024
|
Victoria Eatwell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,230
-0.36%
|
$4,920
$4.65 P/Share
|
|
Oct 03
2024
|
Jessica Snow |
SELL
Open market or private sale
|
Direct |
679
-0.43%
|
$2,716
$4.65 P/Share
|
|
Aug 14
2024
|
Jessica Snow |
SELL
Open market or private sale
|
Direct |
7,816
-4.76%
|
$31,264
$4.32 P/Share
|
|
Aug 05
2024
|
Victoria Eatwell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13
-0.0%
|
$39
$3.98 P/Share
|
|
Jul 02
2024
|
Jessica Snow |
SELL
Open market or private sale
|
Direct |
14
-0.01%
|
$56
$4.02 P/Share
|
|
Jul 02
2024
|
Victoria Eatwell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12
-0.0%
|
$48
$4.02 P/Share
|
|
Jul 01
2024
|
Jessica Snow |
BUY
Grant, award, or other acquisition
|
Direct |
108,538
+39.8%
|
-
|
|
Jul 01
2024
|
William D Baird Iii President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
586,022
+39.58%
|
-
|
|
Jul 01
2024
|
Victoria Eatwell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,864
+41.87%
|
-
|
|
Jun 10
2024
|
Denice Torres |
BUY
Grant, award, or other acquisition
|
Direct |
12,050
+27.63%
|
-
|
|
Jun 10
2024
|
Charles W. Newton |
BUY
Grant, award, or other acquisition
|
Direct |
6,025
+21.03%
|
-
|
|
Jun 10
2024
|
Sarah Js Glickman |
BUY
Grant, award, or other acquisition
|
Direct |
12,050
+30.35%
|
-
|
|
Jun 10
2024
|
Lin Wei |
BUY
Grant, award, or other acquisition
|
Direct |
12,050
+26.84%
|
-
|
|
Jun 10
2024
|
Marcela V. Maus |
BUY
Grant, award, or other acquisition
|
Direct |
12,050
+30.35%
|
-
|
|
Jun 10
2024
|
Casdin Capital, LLC Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,025
+21.03%
|
-
|
|
Jun 03
2024
|
Jessica Snow |
SELL
Open market or private sale
|
Direct |
649
-1.15%
|
$2,596
$4.18 P/Share
|
|
Jun 03
2024
|
Victoria Eatwell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,167
-1.21%
|
$4,668
$4.18 P/Share
|
|
May 03
2024
|
Jessica Snow |
SELL
Open market or private sale
|
Direct |
15
-0.03%
|
$60
$4.91 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.37M
Shares
From
12
Insiders
| Grant, award, or other acquisition | 1.55M shares |
|---|---|
| Open market or private purchase | 817K shares |
Sell / Disposition
153K
Shares
From
6
Insiders
| Open market or private sale | 153K shares |
|---|